Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DYAI 
Dyadic International Inc (DYAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: DYAI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.95% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.85M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 0.94 | 52 Weeks Range 0.71 - 2.20 | Updated Date 09/17/2025 |
52 Weeks Range 0.71 - 2.20 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -134.84% | Operating Margin (TTM) -177.21% |
Management Effectiveness
Return on Assets (TTM) -36.14% | Return on Equity (TTM) -422.64% |
Valuation
Trailing PE - | Forward PE 15.82 | Enterprise Value 35935324 | Price to Sales(TTM) 8.67 |
Enterprise Value 35935324 | Price to Sales(TTM) 8.67 | ||
Enterprise Value to Revenue 10.5 | Enterprise Value to EBITDA -2.93 | Shares Outstanding 36187800 | Shares Floating 26907437 |
Shares Outstanding 36187800 | Shares Floating 26907437 | ||
Percent Insiders 25.17 | Percent Institutions 13.88 |
Upturn AI SWOT
Dyadic International Inc
Company Overview
History and Background
Dyadic International Inc. was founded in 1979. It originally focused on industrial enzyme development and production. Over time, it has evolved to concentrate on its patented C1 gene expression platform for biopharmaceutical and industrial applications.
Core Business Areas
- C1 Gene Expression Platform: Dyadic's primary focus is the C1 gene expression platform, a filamentous fungus used for the production of recombinant proteins and metabolites. This platform is aimed at biopharmaceutical, vaccine, and industrial enzyme markets. They generate revenue through licensing agreements, research and development collaborations, and milestone payments.
Leadership and Structure
Mark Emalfarb is the Founder and CEO. The company has a typical corporate structure with a board of directors and various management teams overseeing research, development, and business operations.
Top Products and Market Share
Key Offerings
- C1 Expression Platform: The C1 platform is licensed to various companies for protein production, enzyme development, and vaccine production. Market share information is not publicly available but the market for biopharmaceutical protein production is large and competitive. Competitors include microbial expression platforms (e.g., E. coli, yeast), mammalian cell culture (e.g., CHO cells), and insect cell culture.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing significant growth, driven by increasing demand for novel therapies and vaccines. The market for protein production platforms is competitive with various technologies available.
Positioning
Dyadic positions itself as offering a cost-effective and scalable alternative to traditional protein production methods. Their competitive advantage lies in the potential for high yields and broad applicability of the C1 platform.
Total Addressable Market (TAM)
The estimated total addressable market for biopharmaceutical manufacturing is in the tens of billions of dollars. Dyadic is positioned to capture a share of this market by offering its C1 platform as a viable alternative or complement to existing technologies.
Upturn SWOT Analysis
Strengths
- Proprietary C1 gene expression platform
- Potential for high protein yields
- Scalability and cost-effectiveness
- Partnerships with established companies
Weaknesses
- Limited commercial revenue
- Dependence on partnerships and licensing agreements
- Competition from established protein production technologies
- History of net losses
Opportunities
- Expanding into new biopharmaceutical applications
- Securing additional licensing agreements
- Developing novel C1-derived products
- Entering new markets
Threats
- Failure to secure additional licensing agreements
- Competition from alternative protein production technologies
- Regulatory hurdles
- Potential for intellectual property disputes
Competitors and Market Share
Key Competitors
- LLY
- AMGN
- GILD
- PFE
Competitive Landscape
Dyadic's competitive advantage lies in its proprietary C1 platform, which offers potential cost and scalability advantages. However, it faces competition from established players with more mature technologies and greater financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by licensing agreements and research collaborations.
Future Projections: Future growth is dependent on securing additional partnerships and commercializing the C1 platform.
Recent Initiatives: Recent initiatives include expanding the C1 platform's applications and pursuing new licensing agreements.
Summary
Dyadic International Inc. focuses on its C1 gene expression platform for biopharmaceutical and industrial applications. The company's proprietary technology offers scalability and cost advantages but faces strong competition. Future success hinges on securing additional partnerships and generating commercial revenue. Financial performance will depend on the success of commercializing its key offering. Investors should be aware of the financial risk since the company has net losses.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on publicly available information and represents a general overview. It should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dyadic International Inc
Exchange NASDAQ | Headquaters Jupiter, FL, United States | ||
IPO Launch date 2004-11-05 | Founder, CEO & Director Mr. Mark A. Emalfarb | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.dyadic.com |
Full time employees 6 | Website https://www.dyadic.com | ||
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.